Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus
- 7 November 2008
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 13 (4) , 449-455
- https://doi.org/10.1016/j.ijid.2008.06.041
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected PatientsA Randomized Controlled TrialJAMA, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected PersonsNew England Journal of Medicine, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Understanding Racial Disparities in HIV Using Data From the Veterans Aging Cohort 3-Site Study and VA Administrative DataAmerican Journal of Public Health, 2003
- Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Comparison of Use of Medications After Acute Myocardial Infarction in the Veterans Health Administration and MedicareCirculation, 2001
- Racial Differences in the Treatment of Early-Stage Lung CancerNew England Journal of Medicine, 1999
- Racial Variation in the Use of Coronary-Revascularization Procedures — Are the Differences Real? Do They Matter?New England Journal of Medicine, 1997